TAC calls for Roche to drop price of cancer drug

2017-02-08 11:06
Treatment Action Campaign members protest against the high price of a life-saving breast cancer drug. (Ihsaan Haffejee, GroundUp)

Treatment Action Campaign members protest against the high price of a life-saving breast cancer drug. (Ihsaan Haffejee, GroundUp)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Johannesburg - Thulani Daki cried as he described to hundreds of protesters outside the Johannesburg office of pharmaceutical company Roche how his mother Thobeka Daki died of cancer.

Thobeka was diagnosed with HER2-positive breast cancer in 2013. She died in her home in the Eastern Cape on November 14, 2016. A drug called trastuzumab manufactured by Roche might have helped her survive, but it was unaffordable, GroundUp reported.

"How many women must die because of the greed of Roche?" asked Daki. "I'm very angry. My mother was not rich and just because of that she was denied access to the required treatment."

The protesters included women living with breast cancer. Many held up placards calling for justice for Thobeka.

Trastuzumab is recommended by the World Health Organisation as an essential medicine for the treatment of HER2-positive breast cancer.

According to a statement by the Treatment Action Campaign (TAC), which organised the protest, clinical trials have demonstrated that providing trastuzumab in addition to chemotherapy, improved the survival of women with early or locally advanced breast cancer by 37%.

R200 000 to R500 000 price tag

Lotti Rutter, campaign manager for the TAC, said trastuzumab is too expensive for the majority of people in South Africa.

"In the private sector, it can cost over R500 000 and in the public sector over R200 000 [for a six-month course].

"So this means that the government, which runs the public health service, does not want to procure the drug because it is so expensive," she said.

Rutter said that health economists have shown that the price of trastuzumab could be reduced to R3 500.

Babalwa Malgas travelled from the Eastern Cape to attend the protest. She wore a pink shirt which bore Thobeka's face. She too is living with HER2-positive breast cancer.

"My life is at stake because of the patent rights given to this pharmaceutical company. I couldn't get access to the medication because money is more important than my constitutional rights and my life," she said.

Negotiations with government

A memorandum handed over to Roche management demanded that the company drop the price of trastuzumab so that all women living with HER2+ breast cancer can access it. The protesters also demanded that Roche cease litigation against companies producing similar versions of trastuzumab and that the company stop extending its patent period on the drug.

The TAC argues that with competition from generic companies the price will come down.

Aadila Fakier of Roche's public policy and communications department signed and accepted the memorandum. She said she noted the concerns of the protesters and that Roche would continue to engage with the relevant stakeholders, including government, on this issue. 

"Roche has been in negotiations with the Department of Health over the past year to improve equitable access to trastuzumab in the public sector.

"We have offered the Department of Health a significantly reduced and cost-effective treatment option. This option supports the testing of breast cancer patients in the public sector, and if positive for the HER2 gene, makes trastuzumab available for the treatment of these patients. A final agreement has however not yet been concluded," read a statement released to the media by Roche. 

Read more on:    tac  |  health  |  cancer

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.
NEXT ON NEWS24X

Inside News24

 
Partner Content
How data is changing investments

Technological disruption is rife in many spheres of business and given the quantity of data available, it’s no surprise that the way in which asset managers work is also changing fast.

Behind the sparkle

Alluring, beautiful and timeless - diamonds are some of the most sought after gems in the world and are a true testament of everlasting brilliance. Let us take you behind the sparkle to show you the history behind this coveted jewel.

/World
 

Fascinating facts about dogs

Think you know a lot about dogs? How many of these facts do you know?

 
 

Paws

Perfectly captured cat snapchats!
Fascinating facts about dogs
Out with the old dog, in with the new
Play with your pet when you're not at home
Traffic Alerts
Traffic
There are new stories on the homepage. Click here to see them.
 
English
Afrikaans
isiZulu

Hello 

Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.


Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Settings

Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.




Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.